An oral formulation of GLP-1 receptor agonist is available and regularly used in the treatment of diabetes and obesity, which would reduce this burden and benefit the level of treatment compliance in future studies, although our study did demonstrate that even daily injections in the context of a clinical trial in Alzheimer’s disease are possible. This evidence concerns the gene GLP1R and early-onset autosomal dominant Alzheimer disease.